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19 Abstract: Neurofilaments (NFs) are structural proteins of neurons 
20 that are released in significant quantities in the cerebrospinal fluid 
21 and blood as a result of neuronal degeneration or axonal damage. 
22 Therefore, NFs have potential as biomarkers for neurologic 
23 disorders. Neural degeneration increases with age and has the 
24 potential to confound the utility of NFs as biomarkers in the 
25 diagnosis of neurologic disorders. We investigated this relationship 
26 in horses with and without neurological diagnosis. While controlling 
27 for horse type (draft, pleasure, and racing), we evaluated the 
28 relationship between serum heavy-chain phosphorylated 
29 neurofilaments (pNF-H) and age, sex, and serum vitamin E 
30 concentrations. Serum pNF-H concentrations increased by 0.002 
31 ng/mL for each year increase in age. There were significant 
32 differences in the serum pNF-H concentration among the type of 
33 activity performed by the horse. The highest serum pNF-H 
34 concentration was found in horses performing heavy work activity 
35 (racehorse) and with lower serum pNF-H concentration found 
36 among light (pleasure riding) and moderate (draft) activity. There 
37 was no significant association between the pNF-H concentration and 
38 sex or vitamin E concentration. Serum pNF-H concentration was 
39 elevated among horses afflicted with EMND and EPM when 
40 compared with control horses without evidence of neurologic 
41 disorders. Accordingly, serum pNF-H concentration can serve as a 
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42 useful biomarker to complement the existing diagnostic work-up of 
43 horses suspected of having EPM or EMND.
44
45 Key words: Biomarker; equine motor neuron disease; equine 
46 protozoal myeloencephalitis; neurofilaments.
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66 1. Introduction
67 Current diagnostic methods used to diagnose equine 
68 neurologic disorders such as equine protozoal myeloencephalitis 
69 (EPM) and equine motor neuron disease (EMND) are based heavily 
70 on clinical examinations and invasive laboratory tests, i.e., tissue 
71 biopsies and cerebrospinal centesis, and definitive diagnosis can 
72 only be determined by autopsy (Dubey et al., 2001; Reed et al., 
73 2013). 
74 Neurofilaments (NFs) are structural proteins of neurons that 
75 are densely located in axons of the neurons (Boylan et al., 2009; 
76 Gresle et al., 2014) and mainly consist of 3 subclasses: light (NF-L), 
77 medium (NF-M), and heavy (NF-H) (Gresle et al. 2014).  These 
78 proteins are released into the cerebrospinal fluid (CSF) and blood as 
79 a result of neuronal degeneration or axonal damage (Inoue et al., 
80 2017; Petzold, 2005). Neurofilaments have been demonstrated to be 
81 stable in blood, serum, or CSF over time, and no effect has been 
82 detected in pNF-H concentrations when freezing CSF or serum 
83 (Gendron et al., 2017; Hamishehkar et al., 2016). The fact that NFs 
84 have a relatively long half-life makes the concentration of NFs in 
85 serum a possible biomarker for neurologic diseases or neuronal 
86 disintegration (Millecamps et al., 2007; Yuan et al., 2009). 
87 Our studies and those of others have confirmed elevated 
88 concentrations of neurofilaments in animals affected with several 
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89 pathologic conditions or trauma (Intan-Shameha et al., 2017; 
90 Nishida et al., 2014). Little is known about the changes in the 
91 concentrations of NFs during the normal aging process. Our 
92 suspicion is that the concentrations of the phosphorylated NFheavy 
93 (pNF-H) in the serum increases with age as a result of progressive 
94 neuronal loss and axonal disintegration. The literature on the 
95 relationship between age and neuronal degeneration is conflicting. 
96 Although one study in humans reported that the serum concentration 
97 of phosphorylated NF-light (pNF-L) increases with age (Burianová 
98 et al., 2015); studies on the relationship between the serum 
99 concentration of NFs and age are lacking in horses. A study in rats 
100 demonstrated non-significant changes in the number of neurons with 
101 age Vågberg et al., 2015). If the serum concentration of NFs 
102 increases significantly with age in the horse, this finding has the 
103 potential to confound the utility of NFs as a test for equine 
104 neurologic disorders. Furthermore, in a previous study we reported 
105 that horses afflicted with EPM had significantly increased 
106 concentrations of pNF-H compared to healthy horses. Since we did 
107 not account for the age of the animals in that report (Intan-Shameha 
108 et al. 2017), we conducted this study to determine if there was a 
109 relationship between pNF-H concentrations and age. 
110 Another factor that has the potential to influence the 
111 concentrations of NFs in animals is treatment with vitamin E. 
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112 Vitamin E is commonly administered to animals and humans for 
113 disease prevention or treatment of neurodegenerative diseases, 
114 including EMND and motor neuron diseases in other species 
115 (Brown et al., 2017; Finno et al., 2017; Mohammed Dr. et al., 2012; 
116 Ng et al., 2017). The impact of serum concentrations of vitamin E 
117 on the concentration of NFs is not clear and has a potential to 
118 confound the utility of this biomarker as a diagnostic parameter for 
119 neurologic disorders. 
120 In this study we aim to investigate the association between 
121 pNF-H and the age of the horse, while controlling for other possible 
122 confounding factors, (effect of serum levels of vitamin E, level of 
123 activity of the horse, and sex) in order to evaluate the potential use 
124 of these proteins as biomarkers for 2 common neurologic disorders 
125 of the horse: EMND and EPM. 
126 2. Materials and methods
127 2.1. Study design, target and study population
128 This cross-sectional study included horses residing in New 
129 York State. The study population included healthy horses and horses 
130 with a confirmed neurologic diagnosis of EMND or EPM. The case 
131 horses were either admitted to the Cornell University Hospital for 
132 Animals (CUHA) or had blood samples submitted to the Animal 
133 Health Diagnostic Center (AHDC). Control horses included horses 
134 admitted to CUHA for evaluation and treatment of non-neurologic 
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135 conditions or horses without reported neurologic clinical signs 
136 whose blood was submitted to the AHDC for determination of 
137 Vitamin E levels.  Horses with or without neurologic disorders were 
138 categorized into 3 activity categories: light (pleasure or trail riding 
139 horses), moderate (working draft horses or low-level event horses) 
140 and heavy (Thoroughbred race horses).
141 2.2 Inclusion criteria 
142 The inclusion criteria for enrollment of case horses with 
143 neurological diseases was a definitive diagnosis of EMND or EPM 
144 (based on necropsy findings that included histopathological 
145 examination of the brain and spinal cord and vitamin E values in 
146 their medical record. All horses without a neurologic disorder (lack 
147 of reporting of neurologic signs) were included as healthy horses. 
148 2.3 Determination of serum pNF-H concentration  
149 The pNF-H assay was conducted using the pNF-H sandwich 
150 enzyme-linked immunosorbent assay (ELISA) kit (ELISA, EMD 
151 Millipore, Billerica, MA). The protocol used chicken polyclonal 
152 antibodies generated against pNF-H, which were pre-coated onto a 
153 96–well plate, later rabbit polyclonal antibodies and a goat anti-
154 rabbit alkaline phosphatase conjugate were used to detect the 
155 captured pNF-H from the samples.
156 The pNF-H ELISA kit uses antibodies specific for pNF-H 
157 from mammalian species, additional ELISA protocol details are 
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158 described previously (Anderson et al., 2008; Intan-Shameha et al., 
159 2017). Frozen serum samples from each horse were thawed prior to 
160 assay. All samples were tested in duplicate and the assay was 
161 performed according to the manufacturer’s protocol. The person 
162 who performed the assays was completely blinded to the clinical 
163 information. The mean absorbance of the pNF-H standard, 
164 measured as optical density (OD), was plotted on a logarithmic 
165 scale. As a result, a standard curve was created and was used to 
166 calculate the pNF-H concentration of each sample (range of 
167 detection was 0.0293 ng/mL to 15 ng/mL), since duplicates were 
168 used for every sample, an average value of each sample was 
169 calculated. 
170 2.4 Determination of vitamin E concentration
171 Serum was harvested from the horse whole blood samples, 
172 and 1 mL of serum was added into a sterile polypropylene 
173 microtubes containing an antioxidant mixture, consisting of 100 mL 
174 of an ethanol mixture of propyl gallate and EDTA. The samples 
175 were then frozen at –75°C until testing. Serum concentrations of α-
176 tocopherol were measured at the AHDC at Cornell University by 
177 means of high-performance liquid-liquid partition chromatography. 
178 Analytes of interest were detected by spectrophotometry (molecular 
179 fluorescence emission at 330 nm for 7.05 minutes) with a tandem 
180 arrangement of a variable-wavelength UV detector and a 
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181 spectrofluorometric detector. The concentration of vitamin E was 
182 reported as µg/ml. Further details on method are delineated 
183 previously (Mohammed et al., 2007).  
184 2.5 Data collection and analysis
185 Data on the age, sex and type of activity (draft, pleasure, or 
186 racing; which recoded into light, moderate, or heavy) of the horse 
187 was acquired from the CUHA horses’ medical records or collected 
188 by personal interviews with the horse’s owner/trainer. 
189 The data was initially reported using frequency distribution 
190 and graphics, and the measure of central tendency (mean or median) 
191 and dispersion (standard deviation and range) were calculated. The 
192 bivariate relationship between each of the factors/variables (age, 
193 vitamin E concentrations and type of horse activity) and the 
194 concentration of pNF-H was assessed using regression analysis or 
195 analysis of variance for categorical variables. In the final analysis, 
196 factors that were significantly associated with the concentrations of 
197 pNF-H in the bivariate analysis were evaluated jointly using the 
198 general linear model to assess the significance of association of each 
199 factor while simultaneously controlling for other factors. The 
200 probability of neurologic diseases (EMND or EPM) was calculated 
201 from the logistic regression analysis equation and the dependent 
202 variable was whether the horse had neurologic disorder or not. Only 
203 horses with vitamin E values were included in this analysis.  All 
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204 statistical analyses were performed using the SPSS v.24 (IBM SPSS 
205 Statistical Software, White Plain, NY) and statistical significance 
206 differences were considered a type I error (p-value) of 0.05. 
207 3.  Results
208 3.1 pNF-H as a function of age, sex and activity
209 A total of 169 horses without clinical signs of neurologic 
210 disease met the inclusion criteria and were enrolled for this part of 
211 the study. Table 1 shows the distribution of the pNF-H horse serum 
212 concentrations by the type of activity, sex and age of the horse. 
213 There was significant variation in the serum neurofilament 
214 concentrations among horses with different levels of work activity 
215 (light, moderate, and heavy).Those horses with heavy activity  
216 (Thoroughbred race horses), had significantly higher serum levels 
217 of neurofilaments compared to either horses with moderate work 
218 activity (working draft horses or low-level event horses) or light 
219 work activity (pleasure horses or trail horses)  (Table 1). There was 
220 no significant difference in the serum concentration of 
221 neurofilaments among horses in our study population based upon 
222 the sex of the horse. 
223 The average age of the healthy horses in our study was 11.65 
224 years (SD = 6.8 years) (Table 1). There was a tendency for the 
225 concentrations of pNF-H to increase with the age of the horse 
226 (Figure 1). The initial correlation (bivariate) between age and the 
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227 level of neurofilaments was evaluated using a regression analysis 
228 with different transformation (linear and second order) to ensure 
229 capturing any variability in age. Although there was significant 
230 positive linear relationship between the age of the horses in this 
231 study and the concentrations of the pNF-H; the concentrations of 
232 pNF-H increased by only 0.002 ng/ml for each year of increase in 
233 age.  
234 3.2 pNF-H concentration and vitamin E concentration 
235 Serum vitamin E concentrations were obtained from 93 
236 healthy horses.  The average serum vitamin E concentration in 
237 healthy horses was 2.56 µg/ml (Table 1). There was no significant 
238 correlation between the concentration of vitamin E and the 
239 concentration of pNF-H in our study (Figure 2) and in the bivariate 
240 analysis.  
241 3.3 Multivariate Analysis 
242 Table 2 shows the results of the multivariate analysis for the 
243 relationship between the age of the horses and the serum 
244 concentrations of pNF-H when controlled for the activity of the 
245 horses. The concentrations of neurofilaments increased by 0.002 
246 ng/ml for each year of increase in age of the horse (regression 
247 coefficient). That means for each year increase in age of the horse 
248 the concentration of pNF-H increases by 0.002 What that means
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249 There was a significant association between the type of 
250 activity of the horse and the concentrations of pNF-H. The adjusted 
251 mean pNF-H values for the reference category of the activity was 0 
252 ng/ml, horses with heavy activity was 0.359 ng/ml which was 
253 significantly higher than that for moderate (0.225 ng/mL) or light 
254 (0.0246 ng/mL) activity horses (Table 2). 
255 3.4 pNF-H and neurologic disorders
256 We investigated the association between serum pNF-H 
257 concentration and the likelihood of neurologic disorders using a 
258 logistic regression analysis. A total of 61 horses with confirmed 
259 diagnosis of EMND (23 horses) or EPM (38 horses) were identified. 
260 The probability of neurologic disorder given the concentrations of 
261 neurofilaments was calculated using the logistic regression analysis 
262 as follows: .  Where P 𝑃(𝑁𝑒𝑢𝑟𝑜𝑙𝑜𝑔 𝑖𝑐) =  
1
1 +  (exp ‒ (𝛼 + 𝛽(𝑝𝑁𝐹𝐻)))
263 (Neurologic) is the probability of neurologic disorders (EMND or 
264 EPM), α is the constant of the logistic regression, and β is the 
265 regression coefficient for the changes in the probability of pNF-H 
266 per unit change in the pNF-H concentrations. In the analysis the 
267 constant value was -3.786 and the regression coefficient was 2.977. 
268 Figure 3 shows the relationship between the probability of 
269 neurologic disorder and the pNF-H serum values. The probability of 
270 a neurologic disorder reaches 0.9 as the concentrations of pNF-H 
271 reaches 2.0 ng/ml (Figure 3).
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272 4. Discussion
273 The long-term objective of our research is to investigate the 
274 usefulness of pNF-H as a diagnostic parameter for the presence and 
275 severity of neurologic disorders in the horse. The use of pNF-H as a 
276 diagnostic marker for neurologic disorders, i.e., amyotrophic lateral 
277 sclerosis (ALS), or brain injuries in humans, has proven to be useful 
278 (Chen et al., 2016; Gaiani et al., 2017; Gendron et al., 2017; Poesen 
279 et al., 2017; Shibahashi et al., 2016). Studies have linked the 
280 concentrations of these proteins to certain neurologic conditions in 
281 humans and in horses (Idland et al., 2017, Takei, 1992). Most of the 
282 aforementioned neurologic conditions, in humans or animals, are 
283 age related and it is not clear whether the observed association with 
284 pNF-H was confounded by the age of the study units—either 
285 humans or animals. Hence, it is imperative to investigate whether an 
286 association between serum concentrations of pNF-H and the 
287 likelihood of neurologic disorders in horses is likely to be 
288 confounded by the age of the horse.
289  The potential confounding effect of age is plausible. It is 
290 common knowledge that the neurons degenerate and die with age, 
291 so as a consequence it is reasonable to expect a proportionate 
292 increase of the concentration of NFs with age. Neurofilaments are 
293 found in both the central and peripheral nervous system (Petzold, 
294 2015). As a consequence of neuronal or axonal damage associated 
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295 with the aging process or trauma, NFs are believed to be released 
296 into the extracellular space increasing the concentration of pNF-H 
297 in the CSF and serum (Petzold, 2015; Steinacker et al., 2016b, 
298 2016a). Several studies have used this finding to develop biomarkers 
299 for neurodegenerative diseases and traumatic conditions in humans 
300 and experimental animals (Intan-Shameha et al., 2017; Kirkcaldie 
301 and Collins, 2016; Yilmaz et al., 2017).
302  This study showed that although there was a positive change 
303 in the relationship between age and serum pNF-H with age, the 
304 degree of change was not  high. Reports in humans have 
305 demonstrated similar association based upon examination of CSF 
306 (Bjerke et al., 2014; Steinacker et al., 2016b, 2016a). The difference 
307 between our study and the aforementioned studies is that in the 
308 human studies the concentrations of pNF-H were measured in the 
309 CSF and not serum. 
310 To the authors’ knowledge, this is the first study to 
311 investigate the association between serum concentration of NFs and 
312 age in the horse.  Since CSF and serum pNF-H concentrations have 
313 a direct proportional relationship, we looked at previous studies that 
314 evaluated the association between serum pNF-H concentrations and 
315 age in human patients. Although several studies demonstrated that 
316 the concentration of pNF-H in the CSF was associated with age-
317 related neurodegeneration in cognitively healthy adults, other 
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
318 studies were not able to make similar conclusions (Idland et al., 
319 2017; Vågberg et al., 2015). Most of these human studies examined 
320 the relationship between age and the CSF-NFs concentrations by 
321 assessing the deterioration in the whole-brain (Bjerke et al., 2014; 
322 Steinacker et al., 2016b, 2016a; Vågberg et al., 2015; Zetterberg, 
323 2017). The consensus among those studies was that there are age-
324 related changes in the human brain tissue that reflect the ageing 
325 process and that concentration of the NFs measured in the CSF 
326 demonstrated high correlation between the NF-L and NF-H. 
327 Whereas in two studies the age was biased towards elderly 
328 individuals, other studies patients’ age range was skewed (Idland et 
329 al., 2017; Steinacker et al., 2016a, Takasaki et al., 2002). 
330 Interestingly, the human study populations included only mature 
331 subjects ranging from 20 to 70 years of age (Vågberg et al., 2015; 
332 Zetterberg, 2017). In our study, horse age ranged from 0.58 to 31 
333 years of age (11.65 mean) and included juvenile individuals.
334 The vitamin E concentrations in serum are known to be 
335 associated with aging in several neurologic disorders in animals and 
336 humans (Divers et al., 2006; Hamishehkar et al., 2016). The criteria 
337 for including horses in the normal category included a cutoff point 
338 for vitamin E of concentrations > 1.5 ug/mL. This cut-off point was 
339 based both upon our clinical experience and experimental findings 
340 (Divers et al., 2006). In the final analysis for assessing the 
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341 association between age and concentrations of vitamin E, only 
342 horses with vitamin E values recorded in the medical record were 
343 included in the study. Since there is an association between the NF 
344 concentrations and age, it is not unreasonable to hypothesize that the 
345 NF serum concentrations might be associated with serum vitamin E 
346 concentration. However, in our study population there was no 
347 significant association between serum concentrations of NF and 
348 serum vitamin E among the healthy horses. To the authors’ 
349 knowledge there is no previous study that examined this association 
350 in blood samples from human or animals. The only study that 
351 indirectly investigated the relationship between vitamin E and pNF-
352 H, did so by examining histopathological changes and concluded 
353 that there was no significant association (Takei, 1992). That 
354 observation is consistent with the findings of this study.
355 Our study demonstrated significant differences in the 
356 concentration of pNF-H among horses performing different levels 
357 of activity. Horses undergoing heavy exercise (Thoroughbred racing 
358 horses) had higher serum pNF-H concentration than horses 
359 undergoing light or moderate (draft, pleasure riding, event horses). 
360 Although there are no previous studies in animals that demonstrated 
361 an association between serum pNF-H concentrations and levels of 
362 activity, several studies in human subjects showed that the serum 
363 pNF-H concentrations are increased among competitive athletes 
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364 (Oliver et al., 2016; Shahim et al., 2017). These studies attributed 
365 the increase of pNF-H concentrations among performing athletes to 
366 increased likelihood of trauma, concussion, or injury. Given the 
367 relatively high level of training activity experienced by 
368 Thoroughbred racehorses, it is reasonable to suggest that the 
369 significantly higher serum levels of pNF-H found in Thoroughbred 
370 racehorses in this study may reflect an increased exposure to 
371 exercise-related trauma in comparison to pleasure or draft horses. 
372 Recent studies have promoted the use of NFs as a diagnostic 
373 biomarker for neurologic conditions in animals and humans 
374 (Disanto et al., 2017; Intan-Shameha et al., 2017; Nishida et al., 
375 2014; Steinacker et al., 2016b, 2016a; Toedebusch et al., 2017). In 
376 our study we explored the potential use of serum pNF-H 
377 concentrations to complement clinical observations and 
378 conventional diagnostic tests in the diagnosis of EMND and EPM 
379 in the horse. A definitive diagnosis for horses afflicted with these 
380 conditions requires histopathological examination of the spinal cord 
381 to detect pathognomonic lesions (Divers, T.J.; Mohammed, H.O.; 
382 Cummings, J.F.; Valentine, B.A.; De Lahunta, A.; Jackson, C.A.; 
383 Summers, 1994; Reed et al., 2016). Both conditions affect the 
384 neurons in the CNS and associated axons leading to the release of 
385 neurofilaments in the serum. This study demonstrated the value of 
386 using elevated concentrations of serum pNF-H as a biomarker to 
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387 predict the probability of the diagnosis of EMND and EPM in 
388 neurologic horses. 
389 Previous studies of the prognostic value of the neurofilament 
390 concentrations had proposed positive cut-off points for the diagnosis 
391 of the respective neurologic condition (Nishida et al., 2014; 
392 Steinacker et al., 2016b, 2016a). Unlike the previous studies, the 
393 authors propose the use of a probability approach for the 
394 interpretation of neurofilaments concentrations in the diagnosis of 
395 EMND or EPM. This approach is based upon two premises: First, 
396 both of these neurologic conditions are progressive in nature and 
397 may have subclinical and clinical phases in which the serum 
398 concentrations of neurofilaments would likely differ. The 
399 probability of the disease would be associated with the specific level 
400 of the serum pNF-H value for a particular patient. Second, it is 
401 envisaged that serum concentrations of neurofilaments would be 
402 only one of the parameters a clinician would use in the diagnostic 
403 work-up, including medical history and clinical examination to 
404 make a specific diagnosis of EMND or EPM.
405  Finally, it can be difficult for equine practitioners to make a 
406 differential diagnosis between hind leg lameness and neurologic 
407 disease, i.e., EPM. The inclusion of serum neurofilament 
408 concentrations in the diagnostic work-up of hind leg lameness of 
409 performance horses has the potential to aid the clinician in making 
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410 an accurate differential diagnosis between EPM and a hindlimb 
411 orthopedic lameness, thus enabling evidence-based treatment of the 
412 condition. 
413 In conclusion, our results showed that although serum 
414 concentrations of pNF-H increased slightly with the age of the 
415 horse, the degree of this increase was not statistically significant. 
416 Serum pNF-H concentrations were not affected by the concentration 
417 of vitamin E in the serum, nor did they vary with the sex of the horse.  
418 Finally, the serum pNF-H concentration did vary with the activity 
419 of the horse, with horses undergoing heavy activities had 
420 significantly higher pNF-H values in comparison to light and 
421 moderate activities. 
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